EchoGo Amyloidosis vs VitalRhythm
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
EchoGo Amyloidosis is an AI-powered screening tool specifically designed for the early detection of cardiac amyloidosis through the analysis of echocardiogram video clips. VitalRhythm, conversely, is an AI-powered cloud-based software for continuous cardiac arrhythmia detection and analysis, integrating with a wearable biosensor for remote patient monitoring. While both are cardiology AI tools, they address distinct cardiac conditions and utilize different data inputs and monitoring approaches.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is an AI-powered screening tool designed to aid in the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. VitalRhythm, on the other hand, is an AI-powered cloud-based software for continuous cardiac arrhythmia detection and analysis, primarily used for remote patient monitoring.
EchoGo Amyloidosis analyzes echocardiogram video clips and integrates seamlessly with existing clinical workflows and IT infrastructure such as PACS, DICOM, and HL7. VitalRhythm analyzes continuous ECG signals from the VitalPatch biosensor and displays detected arrhythmias for review by healthcare professionals via the VistaCenter web application.
EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis based on the analysis of echocardiographic markers. VitalRhythm detects and displays various cardiac arrhythmias, including atrial fibrillation, AV block, supraventricular tachycardia, ventricular tachycardia, and pauses, for review by healthcare professionals.
EchoGo Amyloidosis has a high diagnostic accuracy with 85% sensitivity and 93% specificity for cardiac amyloidosis detection, performing consistently across different CA subtypes. VitalRhythm utilizes a proprietary deep learning-based algorithm for continuous ECG signal analysis, and performance testing demonstrated sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy exceeding 95% for detection of major arrhythmias.
For EchoGo Amyloidosis, inpatient analysis is covered by Medicare with an NTAP Code ICD-10 XXE2X19 at $1,000 per analysis, and outpatient analysis has HCPCS Code C9786 (Clinical APC Code 574) for $285 per analysis, covered by Medicare and select commercial insurers. VitalRhythm's pricing is 'contact for quote,' and specific reimbursement codes are not provided in the given information.